We proposed to remove the SDOH measures beginning with the CY 2025 reporting period under removal Factor 8 as the costs associated with the measure outweigh the benefit of its continued use in these programs ( 419.46(i)(3)(i)(H), 419.95(e)(3)(i)(H), and 416.320(c)(2)(viii), respectively)
long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
Sleep quality directly impacts your body's ability to produce antioxidants, including glutathione
Charles Wolfe:nothing to disclose
The graph shows the cumulative number of records in Scopus in the period of 19942025
